Sjögren-Larsson syndrome (SLS) is a rare inherited condition defined by three features that appear together: scaly skin from birth (ichthyosis), stiff and spastic leg muscles, and intellectual disability. It stems from a deficiency of a single enzyme involved in breaking down fatty molecules, and the consequences reach the skin, brain, and eyes simultaneously. First recognized in Sweden, where it remains most concentrated, SLS is now documented worldwide and poses challenges that span nearly every medical specialty.
The Genetic Cause
SLS follows an autosomal recessive inheritance pattern, meaning a child must receive a faulty copy of the responsible gene from each parent to develop the condition. The gene in question is ALDH3A2, located on chromosome 17. It encodes an enzyme called fatty aldehyde dehydrogenase (FALDH), which normally converts long-chain fatty aldehydes into fatty acids during lipid metabolism.1PubMed. Sjögren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2) When both copies of the gene carry mutations, FALDH activity drops to a fraction of normal levels, and those fatty aldehydes accumulate instead of being safely processed.2PubMed Central. Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency
The buildup of these unprocessed fatty aldehydes is toxic. In the skin, it disrupts the lipid layers that keep water from escaping. In the brain, it damages the fatty sheaths that insulate nerve fibers. In the retina, it alters the delicate lipid balance needed for normal vision. One defective enzyme, in other words, explains why SLS hits so many different tissues at once.
Dozens of different mutations in ALDH3A2 have been catalogued, including deletions, missense changes, and insertions.3Brain. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren–Larsson syndrome The syndrome has a notably high prevalence in northern Sweden owing to a founder effect in that population, but cases have been identified across Europe, the Middle East, North Africa, and elsewhere.4PubMed Central. Sjogren-Larsson Syndrome: Mechanisms and Management
What Happens to the Skin
Ichthyosis in SLS is usually present at birth or appears within the first few weeks of life. The skin is dry, thickened, and covered with fine to plate-like scales that tend to be most prominent on the trunk, neck, and limbs. Unlike some other forms of ichthyosis, the scaling in SLS often has a yellowish-brown tint and is accompanied by intense itching, a feature that significantly affects daily comfort.
The underlying problem is a structural one. The outermost layer of the skin relies on tiny lipid-filled packets called lamellar bodies to build a water-tight barrier. In SLS, those lamellar bodies are abnormal: many have disrupted outer membranes or are missing their lipid contents entirely. Some get trapped inside cells and never release their payload. As a result, the organized lipid sheets that should seal the skin become patchy and disorganized, and water leaks out through the gaps.5PubMed Central. Ichthyosis in Sjögren–Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion This leaky barrier also makes the skin more vulnerable to irritation and infection, compounding the itching that many patients describe as one of their most troublesome symptoms.
Neurological Features
Spasticity, or abnormally tight and stiff muscles, is the second pillar of the SLS triad. It typically affects both legs (spastic diplegia), though some individuals have involvement of all four limbs (spastic quadriplegia).6Brain Disorders. Sjögren Larsson syndrome: A case study with unique mutation The spasticity becomes apparent in infancy or early childhood as motor milestones are delayed. Many children with SLS learn to walk with assistive devices, while others remain wheelchair-dependent. The degree of spasticity varies, but it is a lifelong feature that tends to worsen without active management.
Intellectual disability in SLS ranges from mild to moderate.7PubMed Central. Sjögren-Larsson Syndrome: A Rare Presentation With Developmental Delay Children typically acquire speech, though it may be delayed, and can participate in educational programs adapted to their level. Severe intellectual disability is uncommon.
Brain imaging sheds light on why the neurological problems occur. MRI scans consistently show abnormal white matter signal, particularly in regions close to the brain’s fluid-filled ventricles. White matter is composed largely of myelin, the fatty insulation around nerve fibers. In SLS, myelination is delayed during development and remains mildly deficient afterward.8American Journal of Neuroradiology. MR Imaging and Proton MR Spectroscopic Studies in Sjögren-Larsson Syndrome: Characterization of the Leukoencephalopathy This white matter damage, sometimes described as leukoencephalopathy, is consistent with the toxic effect of accumulated fatty aldehydes on the lipid-rich myelin sheaths.9PubMed Central. Sjögren-Larsson syndrome: a rare disease of the skin and central nervous system
Eye Involvement
Nearly all individuals with SLS develop eye abnormalities, though these can be easy to miss in early childhood. The most distinctive finding is a collection of tiny glistening white dots scattered across the retina, considered virtually unique to the condition.10PubMed Central. Sjogren-Larsson Syndrome: Mechanisms and Management Under closer examination, the macula (the central part of the retina responsible for sharp vision) typically shows a crystalline pattern of deposits and small fluid-filled cysts. Patients with SLS also lack normal macular pigment, which in healthy eyes helps filter damaging blue light.11PubMed. Patients with Sjögren-Larsson syndrome lack macular pigment
In practical terms, this translates to reduced visual sharpness and sensitivity to light (photophobia). As patients age, the crystalline deposits and subretinal material tend to progress, and macular thinning can develop.12PubMed Central. Ophthalmic Findings in Late Stage Sjogren-Larsson Syndrome Regular eye examinations are important for tracking these changes, though no treatment currently reverses the retinal pathology.
Why Preterm Birth Is So Common
A striking feature of SLS that many people overlook is the high rate of preterm delivery. In a study that tracked pregnancies of affected children, about three quarters were born before 37 weeks, with an average gestational age of roughly 35 weeks. Notably, the pregnancies themselves were generally uncomplicated and birth weight was appropriate for gestational age, meaning these babies were not growth-restricted, just arriving early.13PubMed. Preterm birth in Sjögren-Larsson syndrome Healthy siblings of those same children had a preterm birth rate of about 7%, in line with the general population. The prematurity in SLS appears to be an intrinsic part of the condition rather than a consequence of the spasticity or any pregnancy complication. The exact mechanism is not fully understood, but the widespread lipid abnormality caused by FALDH deficiency may alter fetal membranes or the signals that trigger labor.
For clinicians, this pattern has a practical implication: a newborn who presents with scaly skin and was born several weeks early should raise suspicion for SLS, even before neurological signs become apparent.
How SLS Is Diagnosed
Because the three hallmark features overlap with other genetic conditions involving ichthyosis or spasticity, a clinical suspicion of SLS needs biochemical or genetic confirmation. Historically, the gold standard has been measuring FALDH enzyme activity in cultured skin cells. In SLS, that activity is drastically reduced, typically to less than a tenth of normal levels.14Brain. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren–Larsson syndrome
A less invasive approach takes advantage of the fact that FALDH is also needed to break down a signaling molecule called leukotriene B4 (LTB4). In people with SLS, urine concentrations of LTB4 and a related metabolite are sharply elevated, while a downstream breakdown product is absent.15PubMed. Defective metabolism of leukotriene B4 in the Sjögren-Larsson syndrome A simple urine test can therefore flag the enzyme deficiency without requiring a skin biopsy. Molecular genetic testing of the ALDH3A2 gene provides definitive confirmation by identifying the specific mutations involved and also enables carrier testing for family members and prenatal diagnosis in subsequent pregnancies.
Treating the Skin
There is no cure for SLS, so management focuses on reducing symptoms and improving comfort. For the ichthyosis, emollients and keratolytics (creams that soften and remove thickened skin) are the first step. Many families find that regular bathing followed by generous moisturizer application helps control scaling, though it never eliminates it.
Oral retinoids offer a more substantial improvement. Acitretin, given at a low maintenance dose, has been shown to decrease the severity of ichthyosis in children with SLS and to meaningfully improve quality of life for both patients and their caregivers.16PubMed. Clinical and molecular characterization and response to acitretin in three families with Sjögren-Larsson syndrome Retinoids come with their own side effects, including dry lips and, with long-term use, potential effects on bone growth and liver function, so ongoing monitoring is needed. Still, for many families the trade-off is well worth it given how much the itching and scaling affect daily life.
Managing Spasticity
Spasticity management in SLS draws from the same toolkit used for cerebral palsy and other conditions involving upper motor neuron dysfunction. Physical therapy, stretching, and orthotic devices aim to maintain range of motion and functional mobility. Oral medications like baclofen can reduce muscle tone to some degree.
For more severe spasticity that does not respond well to oral medications, intrathecal baclofen therapy, which delivers the drug directly into the spinal fluid through an implanted pump, has shown promising results. In reported cases, pump implantation led to measurable decreases in muscle stiffness and functional improvements noticed by parents and caregivers.17PubMed Central. Intrathecal Baclofen Therapy for the Treatment of Spasticity in Sjögren-Larsson Syndrome Botulinum toxin injections into specific muscle groups are another option for targeted spasticity relief.
Because SLS affects multiple organ systems simultaneously, effective care typically requires coordination among dermatologists, neurologists, ophthalmologists, orthopedic specialists, rehabilitation therapists, and dental professionals.18BMJ Case Reports. Multisystem manifestations of Sjögren-Larsson syndrome in early childhood and its dental implications Building a team early matters, because addressing the skin, the muscles, and the eyes in a coordinated way tends to produce better outcomes than treating each system in isolation.
Dietary Approaches and Why They Failed
Given that SLS is fundamentally a disorder of fat metabolism, researchers tried the seemingly logical step of modifying the diet. Children ranging from infants to school age were placed on a low-fat diet supplemented with medium-chain fatty acids, which bypass the metabolic step requiring FALDH. The results were disappointing: blood levels of the accumulated fatty alcohol did not change, and neither the skin lesions nor the neurological symptoms improved.19PubMed. Unsuccessful dietary treatment of Sjögren-Larsson syndrome Even starting the diet in early infancy made no difference. The likely explanation is that the body produces enough long-chain fatty aldehydes internally, through normal cell membrane turnover, that restricting dietary fat cannot reduce the toxic load to a meaningful degree.
Research Into Future Treatments
The fact that SLS is caused by a single enzyme deficiency makes it, at least conceptually, a candidate for gene therapy. In laboratory experiments, researchers used a viral vector to deliver a working copy of the FALDH gene into cells that were engineered to lack the enzyme. The treated cells regained normal FALDH activity and became resistant to the toxic effects of fatty aldehydes that would otherwise kill them.20PubMed. Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjogren-Larsson syndrome This was a proof-of-concept in a dish, not a treatment in patients, but it demonstrated that restoring the missing enzyme can reverse the cellular damage.
Beyond gene therapy, other experimental avenues include drugs designed to boost whatever residual FALDH activity a patient’s mutant enzyme still has, compounds that might reduce the overall burden of fatty aldehydes through alternative detoxification pathways, and antioxidants aimed at limiting the secondary damage those aldehydes cause.21PubMed Central. Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome None of these has advanced to clinical trials in patients yet, and the rarity of SLS makes recruiting for such trials inherently difficult. But the biochemical clarity of the disease, one gene, one enzyme, one class of toxic substrate, makes it a more tractable target for precision therapies than many other rare neurological conditions.
Daily Life and Quality of Life
Living with SLS means navigating a combination of challenges that few other conditions bundle together. When researchers surveyed patients and their caregivers across a wide age range (11 to 58 years), the median quality-of-life score came in at 73 on a 100-point scale, but with enormous variation: some individuals scored as low as 26 while others reached 100.22PubMed. Daily Functioning and Quality of Life in Patients with Sjögren-Larsson Syndrome The three problems reported most frequently were itchy skin, limited mobility, and dependence on others for daily activities.
That itching deserves emphasis because it is easy to underestimate. Many caregivers describe it as the single most distressing symptom on a day-to-day basis, surpassing even the mobility limitations. It disrupts sleep, makes concentration harder, and can lead to skin damage from scratching. When acitretin or aggressive moisturizing brings the itching under better control, families often report a disproportionately large improvement in overall well-being, precisely because itching had been silently dragging down every other aspect of daily functioning.
Mobility limitations shape the physical environment. Most individuals with SLS require a wheelchair or walking aids by school age, which means homes, schools, and workplaces need to be accessible. Because intellectual disability in SLS is usually mild to moderate, many affected individuals can participate in adapted educational programs and, with appropriate support, lead socially engaged lives. The degree of independence varies widely, but the condition is compatible with meaningful participation in community activities, especially when the spasticity and skin symptoms are well managed.
Conditions That Can Look Similar
Several other genetic disorders share one or two features of SLS but not all three, which can lead to diagnostic confusion. Other forms of congenital ichthyosis, some of which are also autosomal recessive, can mimic the skin findings but lack the neurological component. Cerebral palsy can explain spasticity and intellectual disability but does not cause ichthyosis. Refsum disease, another disorder of lipid metabolism, produces ichthyosis and neurological problems but with a different pattern of nerve damage and without the characteristic retinal crystals.
The combination of all three cardinal features, especially when accompanied by the distinctive glistening dots in the retina and a history of preterm birth, strongly points toward SLS.23Brain. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren–Larsson syndrome Once the clinical picture raises suspicion, the urine LTB4 test or enzyme assay can distinguish SLS from its mimics quickly. Genetic testing then seals the diagnosis and opens the door to family counseling about recurrence risk, which is one in four for each subsequent pregnancy when both parents are carriers.